sellWeak cluster of 210b5-1 plan
Carl Dambkowski sold $192k of APGE
Chief Medical Officer at Apogee Therapeutics, Inc.. 4,085 shares at an average of $46.94, traded Jan 2, 2025, filed Jan 3, 2025.
Warning score
0Value
$192k
4,085 shares
Holdings after
255,348
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +12Trade size$192k at market
- 0Share of holdings soldSold 1.6% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-000956, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2025 | MOption exercise Common Stock10b5-1 | +1,360 | $22.86 | $31k | 259,433 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -1,499 | $46.42 | $70k | 257,934 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -2,486 | $47.21 | $117k | 255,448 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -100 | $47.92 | $4,792 | 255,348 | Jan 3, 2025 |
| Jan 2, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,360 | $0.00 | $0 | 172,170 | Jan 3, 2025 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $11M 80,000 shares | -7% | |
| 33Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $3.5M 26,400 shares | -13% | |
| 38Weak | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.7M 20,000 shares | -2% | |
| 5Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $433k 5,500 shares | -3% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.6M 20,000 shares | -2% | |
| 12Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $463k 5,500 shares | -3% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $164k 2,000 shares | -1% | |
| 22Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $180k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.7M 20,000 shares | -2% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $170k 2,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.